AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01969357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg SP2086
Description: Tablets(n=1),100 mg strength+tablets(n=3) once 0 mg daily for 84 days
Study NCT01969357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg SP2086
Description: Tablets(n=2),100 mg strength+tablets(n=2) 0mg once daily for 84 days
Study NCT01969357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mg Sitagliptin
Description: Tablets(n=1),100 mg strength+tablets(n=3),0 mg strength once daily for 84 days
Study NCT03238066 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: HDR/PDR brachytherapy
Study NCT03238066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: Interstitial hyperthermia
Study NCT04217720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNS-301
Description: SNS-301 (1x 1011 dose/1ml) ID injection every 3 weeks for 4 doses then every 6 weeks for 6 additional doses, and thereafter every 12 weeks up to 24 months.
Study NCT04910490 — intervention group
Intervention type: OTHER
Intervention: No interventions - retrospective data collection
Description: No new/additional patients will be enrolled within this project.
Study NCT04347291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAMS 2.0
Description: FAMS components include monthly phone coaching following a semi-structured protocol plus daily automated text message support to the patient participant and less frequent automated text messages to their support person, if enrolled.
Study NCT04347291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Print Materials
Description: Quality print materials about diabetes management provided upon enrollment and in quarterly study newsletters.
Study NCT04347291 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Print Materials
Description: Quality print materials about diabetes management provided upon enrollment and in quarterly study newsletters.
Study NCT01632709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: one injection of 10ml of .25%
Study NCT01632709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dry needling
Study NCT03314025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin Hydrochloride 0.4 MG
Description: Peri-operative therapy of Tamsulosin Hydrochloride 0.4 milligrams daily for a total of 7 days.
Study NCT03314025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Peri-operative therapy of a Placebo oral capsule daily for a total of 7 days.
Study NCT03314025 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Foley catheter
Description: Every patient with a post-operative urinary retention will have a foley catheter, as standard of care.
Study NCT03314025 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley catheter
Description: Every patient with a post-operative urinary retention will have a foley catheter, as standard of care.
Study NCT04611698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baha sound processor BA400
Description: Baha sound processor BA400 is a cochlear implant designed specifically for soft tissue preservation.
Study NCT03735602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: perceptual training
Description: orientation discrimination task
Study NCT00220701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lexapro (escitalopram)
Description: antidepressant drug selective serotonin reuptake inhibitor (SSRI)
Study NCT00220701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexapro (escitalopram)
Description: antidepressant drug selective serotonin reuptake inhibitor (SSRI)
Study NCT03841032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone, BAY1183345
Description: Lotion, for 4 weeks
Study NCT00706745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: oil rich in cis9, trans11 conjugated linoleic acid
Description: An oil rich in cis9, trans11 conjugated linoleic acid (cis9,trans11-CLA). Of the total amount of CLA in the oil, 80% is cis9, trans11-CLA and 20% trans10, cis12-CLA. In total 4 grams of oil will be given daily. The oil will be taken in the form of soft gel capsules. Two capsules will be taken in the morning and two in the evening.
Study NCT00706745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: oil rich in cis9, trans11 conjugated linoleic acid
Description: An oil rich in cis9, trans11 conjugated linoleic acid (cis9,trans11-CLA). Of the total amount of CLA in the oil, 80% is cis9, trans11-CLA and 20% trans10, cis12-CLA. In total 4 grams of oil will be given daily. The oil will be taken in the form of soft gel capsules. Two capsules will be taken in the morning and two in the evening.
Study NCT00706745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: identical placebo capsules.
Study NCT00706745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identical placebo capsules.
Study NCT04360031 — intervention group
Intervention type: DRUG
Intervention: Tacrolimus
Description: Tacrolimus and Mycophenolate Mofetil are given in accordance with patient's current regimen
Study NCT05014308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezoelectric Alveolar Decortication, fibrotomy
Study NCT00802451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Study NCT01003275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: Two 1 mcg soft gels by mouth daily for 8 weeks
Study NCT01003275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Two soft gels by mouth daily for 8 weeks
Study NCT02289950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Farletuzumab
Description: Farletuzumab will be administered intravenously (IV) weekly
Study NCT02289950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously (IV) weekly
Study NCT04654104 — intervention group
Intervention type: OTHER
Intervention: check immune check points
Description: we will evaluate the expression of immune check points
Study NCT04585321 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Diclofenac Sodium 140mg Medicated Plaster
Description: Part 1: two seven-day study periods, separated by at least 7 days of wash-out. In the first period, a single plaster of Test Drug or Reference Drug will be applied on the back (lumbar region) for seven consecutive days. In the second period, a single plaster of the Reference Drug or Test Drug will be applied on the back (lumbar region) daily for seven consecutive days.~Part 2: two seven-day study periods separated by at least 7 days of wash-out. In the first period, the Test Drug or Reference Drug plaster will be applied on the back (lumbar region) twice a day. In the second period, the Reference Drug or Test Drug plaster will be applied on the back (lumbar region) twice a day.
Study NCT04585321 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac
Description: Part 1: two seven-day study periods, separated by at least 7 days of wash-out. In the first period, a single plaster of Test Drug or Reference Drug will be applied on the back (lumbar region) for seven consecutive days. In the second period, a single plaster of the Reference Drug or Test Drug will be applied on the back (lumbar region) daily for seven consecutive days.~Part 2: two seven-day study periods separated by at least 7 days of wash-out. In the first period, the Test Drug or Reference Drug plaster will be applied on the back (lumbar region) twice a day. In the second period, the Reference Drug or Test Drug plaster will be applied on the back (lumbar region) twice a day.
Study NCT01840189 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cortef
Description: Treatment A is oral hydrocortisone replacement ( Cortef 5 mg) administered according to weight-adjusted doses for 2 months
Study NCT01840189 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Solu-cortef
Description: Treatment B is continuous subcutaneous hydrocortisone infusion with the initial standard dose of 10mg/m2/24hrs. Body surface area will be calculated according to the nomogram from the formula of Du Bois and Du Bois.~This part of the study will take 2 months.
Study NCT01690442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples Based HIV/STI Risk Reduction Intervention (CHSR)
Description: The intervention includes a combination of empowerment and couple self-efficacy building strategies, which are employed to help couples overcome resistance to risk reduction.
Study NCT01690442 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Renaissance Wellness Promotion (WP)
Description: This intervention employs a psychoeducational approach to promote wellness, focusing on: maintaining a healthy diet on a low budget, exercising and fitness, stress reducing strategies and specific health related issues that affect IDUs, such as overdose.
Study NCT01643837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: OMT - Sacral Ligamenotus Articular Release; OMT - Lumbar Spine (L1-L2) and Lower Thoracic Spine (T10-12) Ligamentous Articular Release; OMT - Upper Thoracic Spine Ligamentous Articular Release (T1-T8); OMT - Cervical Spine Ligamentous Articular Release (C5-C7); OMT - Suboccipital Myofascial Release; OMT - Clavicular Ligamentous Articular Release; OMT - First Rib Ligamentous Articular Release; OMT - Ribs 2-8 Ligamentous Articular Release; OMT - Pectoral Pull; OMT - Sternal Ligamentous Articular Release; OMT - Direct Myofascial Release of the Diaphragm; OMT - Thoracic Lymphatic Pump; OMT - Fascial Release of Breast Tissue
Study NCT01643837 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Osteopathic Manipulative Light Touch Protocol (LT)
Description: LT - Sacral Region; LT - Lumbar Spine and Lower Thoracic Region; LT - Upper Thoracic Spine Region; LT - Cervical Spine Region; LT - Suboccipital Region; LT - Clavicles; LT - First Ribs; LT - Ribs 2-8; LT - Pectoralis Muscles; LT - Sternum; LT - Respiratory Diaphragm; LT - Upper Thoracic Cage; LT - Lower Thoracic Cage
Study NCT01934296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa PC+S
Description: Surgical implantation of Activa PC+S as one component of a therapeutic DBS system implantation
Study NCT05291078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A transcutaneous trigeminal nerve stimulator: High Frequency
Description: 30min/day, at least 5 to 7 times a week
Study NCT05291078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A transcutaneous trigeminal nerve stimulator: Low Frequency
Description: 30min/day, at least 5 to 7 times a week
Study NCT05291078 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: A transcutaneous trigeminal nerve stimulator: Sham
Description: 30min/day, at least 5 to 7 times a week
Study NCT05291078 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sound Therapy
Description: Notch Therapy at least 30min/day, at least 5 to 7 times a week
Study NCT05291078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sound Therapy
Description: Notch Therapy at least 30min/day, at least 5 to 7 times a week
Study NCT01586858 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational study of subjects previously enrolled in the RAVE trial
Study NCT00967538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept 50 mg
Description: All patients will receive etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
Study NCT01625026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obeticholic acid
Description: Obeticholic acid 25 mg/day in three weeks
Study NCT01625026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to obeticholic acid
Study NCT03141203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: 10mg vial for Injection
Study NCT03141203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 60mg vial for injection
Study NCT00855842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: osmotic dilator insertion
Description: osmotic dilators are placed in the cervix to cause cervical dilation
Study NCT03466957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printed applicator
Description: add-on cap for oblique needles, 3D printed Vienna-like applicator, individual vaginal cylinder for intracavitary/interstitial application
Study NCT01502566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Intervention
Description: Children/mothers allocated to this arm will receive an pamphlet with key information on dental caries prevention, together with oral instructions about how to avoid dental caries.
Study NCT01715038 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LNS-PLW
Description: Dietary supplement: Lipid-based nutrient supplement~Lipid-based nutrient supplement for pregnant and lactating women (LNS-PLW)~Daily dose of LNS-PLW will be 20 g, packaged in one sachet
Study NCT01715038 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LNS-Child
Description: Dietary supplement: Lipid-based nutrient supplement~Lipid-based nutrient supplement for infants and young children (LNS-Child)~Daily dose of LNS-Child will be 20 g, packaged in two 10 g sachets
Study NCT01715038 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MNP
Description: Dietary supplement: Micronutrient powder~Micronutrient powder for infants and young children (MNP)~The MNP for children will be packaged in 1 g sachets, so that each day, the child will consume one sachet.
Study NCT01715038 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IFA
Description: Dietary supplement: Iron and folic acid nutrient supplement~Iron-folic acid tablets for pregnant and lactating women~Daily dose of iron-folic acid supplement will be one tablet containing 60 mg iron and 400 mcg folic acid
Study NCT01715038 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IFA
Description: Dietary supplement: Iron and folic acid nutrient supplement~Iron-folic acid tablets for pregnant and lactating women~Daily dose of iron-folic acid supplement will be one tablet containing 60 mg iron and 400 mcg folic acid
Study NCT01975064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol will be infused individually for a sufficient level of anesthesia during the entire surgical procedure.
Study NCT01975064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane will be administered by vaporizer individually for a sufficient level of anesthesia during the entire surgical procedure.
Study NCT00237549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: optimised treatment
Description: The intervention targeted individual patients and the Primary Care Team. Practitioners were trained in a target driven, intensive multifactorial approach including lifestyle advice (smoking cessation, physical activity 30 min./day and healthy diet) and pharmacological treatment with the aim of reducing the complications of diabetes as described in protocol.~The training included meetings, practice visiting, written feed back reports and reminders on controls.
Study NCT03155984 — intervention group
Intervention type: DRUG
Intervention: Anti-CD20 antibody
Description: All patients receiving anti-CD20 therapy (rituximab, ofanumumab, obinutuzumab) for hematological malignancies
Study NCT00950807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: long-acting muscarinic receptor antagonist; 18mcg once-daily
Study NCT00950807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive/ excipients only
Study NCT00950807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573179
Description: GSK573179 investigational drug
Study NCT06388655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile neurofeedback
Description: The participants were randomly assigned to the MNF active (N=31) or sham control (N=30) groups. The MNF program was administered using a mobile app (equipped with a headset with a 2-channel EEG sensor) for 30 min/day, 3 days/week, for 3 months.
Study NCT06388655 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham mobile neurofeedback
Description: The sham neurofeedback was implemented through presenting randomized game outcomes, independent of real measurements. The scoring distribution was meticulously adjusted to achieve a realistic spectrum of results, prioritizing median scores to uphold uniformity in user experience.
Study NCT01587222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin
Description: Albumin (20%) 1g/kg iv on day 1 and 80 g every 2 weeks during a period of 12 weeks.
Study NCT01587222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: Oral midodrine 5 mg / 8 hours for 12 weeks. The dose may be increased on day 7 10mg/8h.~If creatinine does not decrease ≥ 25% and systolic blood pressure is bellow 150 mmHg and diastolic 90 mmHg doses will be changed.
Study NCT01587222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Octreotide by subcutaneous injection 0.1 mg every 8 hours for 12 weeks. The dose may be increased to 0.2 mg / 8 h on day 7.~If creatinine does not decrease ≥ 25% and systolic blood pressure is bellow 150 mmHg and diastolic 90 mmHg doses will be changed.
Study NCT03395106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent source
Description: Having a parent feature prominently in a news story
Study NCT03395106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doctor source
Description: Having a doctor feature prominently in a news story
Study NCT03395106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deliberative content
Description: News story content includes process of weighing the risks/benefits of vaccinating, the importance of vaccines for community protection, and concludes with a recommendation to vaccinate.
Study NCT03395106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intuitive content
Description: News story content focuses on the consequences of not vaccinating (including vaccine preventable diseases) and the decisional regret.
Study NCT03198052 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR
Description: CAR-T cells injection: (1-10×10e6/kg CAR-T for each treatment; 3 or more cycles.
Study NCT00863200 — intervention group
Intervention type: BEHAVIORAL
Intervention: Telephone Intervention
Description: Symptom information will be collected using an automated telephone system, approximately 5 minutes per week.
Study NCT00863200 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires & Interviews
Description: 3 questionnaires and one-on-one interviews during 3 regularly scheduled clinic visits.
Study NCT00003351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT03745274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GHB04L1
Description: Solution
Study NCT03745274 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Buffer solution
Study NCT02037932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.
Description: Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.
Study NCT01195727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Study NCT01302951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Description: The patients receive MXF 400 mg as one hour intravenous infusion at randomized timed intervals prior to liver resection.
Study NCT03919526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19/CD22 CAR-T cells
Description: Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-CD22 CARs
Study NCT03919526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2/d
Study NCT03919526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300mg/m2/d
Study NCT03963011 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Bowel Ultrasound
Description: Ultrasound imaging of the bowel
Study NCT03224429 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative Interviews Decisional Needs Assessment
Description: Subjects will participate in an open-ended interview regarding type of sickle cell disease, complications, current treatment, and experiences with decision making and sickle cell treatment. Participants will be asked to describe what is important when making health care decisions. Treatment options (hydroxyurea, chronic or monthly blood transfusions, and bone marrow transplantation) will be discussed as well as how a web-based decision aid tool should be developed. The interview will be audio recorded and will take 45 to 60 minutes to complete.